Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 14/20 | 0.42 |
| ▸ | THRB | P10828 | 14/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5791574 | 0.88 | THRA (0.52) | THRATHRBATMCYP2C8CYP2C9 | |
| SCHEMBL6490396 | 0.82 | ATM (0.41) | THRATHRBATMKMT2AL3MBTL1 | |
| SCHEMBL5758004 | 0.82 | THRB (0.46) | THRATHRBATMCYP2C8CYP2C9 | |
| SCHEMBL10419933 | 0.74 | THRA (0.45) | THRATHRBATMCYP2C8CYP2C9 | |
| SCHEMBL6475079 | 0.74 | THRA (0.34) | THRATHRBATMCYP2C9KMT2A | |
| SCHEMBL6454151 | 0.72 | THRA (0.32) | THRATHRBATMKMT2AL3MBTL1 | |
| SCHEMBL5760588 | 0.71 | MEN1 (0.55) | THRATHRBKMT2AMEN1 | |
| SCHEMBL5566123 | 0.70 | ATM (0.45) | THRATHRBATMKMT2AL3MBTL1 | |
| SCHEMBL10408308 | 0.68 | THRA (0.55) | THRATHRBATMKMT2AL3MBTL1 | |
| SCHEMBL11471529 | 0.66 | THRA (0.54) | THRATHRBATMCYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6911444-B2 | Non-steroidal IL-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors | JANSSEN PHARMACEUTICS N.V. (BE) | 2005-06-28 | — | — | US | disclosed |
| US-6894046-B2 | IL-5 inhibiting 6-azauracil derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-17 | — | — | US | disclosed |
| US-20030114453-A1 | Non-steroidal IL-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-06-19 | — | — | US | disclosed |
| EP-1114046-B1 | INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2003-04-23 | — | — | EP | disclosed |
| EP-1114046-A1 | INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES | Janssen Pharmaceutica N.V. (BE) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000017195-A1 | INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-03-30 | — | — | WO | disclosed |
| EP-0987265-A1 | Interleukin-5 inhibiting 6-azauracil derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114453-A1 | Non-steroidal IL-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors | IL5, IL15, IL15RA | THRA 3831/4885THRB 4010/4885ATM 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.